

**APPROVED**

**By Patrick S. Riggins at 11:13 a**

**From:** Riggins, Patrick  
**To:** ["Margarita Aguilera"](#)  
**Cc:** [Chamrin, Ronald](#)  
**Subject:** RE: Information Request for BLA 125603\0 (original application) MACI™ (matrix applied characterized autologous cultured chondrocytes) Autologous Implantation  
**Date:** Tuesday, January 19, 2016 9:48:00 AM

---

Margarita,  
I have discussed with the Epidemiology reviewer and having the PVP in by January 28 is acceptable.  
Regards,  
Pat Riggins

Patrick S. Riggins, Ph.D.  
Branch Chief  
Regulatory Management Staff  
Office of Cellular, Tissue, and Gene Therapies  
Center for Biologics Evaluation and Research  
Food and Drug Administration  
Bldg 71/Room 5236  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
Phone: (240)402-8346  
Fax: (301)595-1303

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone."

---

**From:** Margarita Aguilera [mailto:[maguilera@vcel.com](mailto:maguilera@vcel.com)]  
**Sent:** Monday, January 18, 2016 4:14 PM  
**To:** Riggins, Patrick  
**Cc:** Chamrin, Ronald  
**Subject:** FW: Information Request for BLA 125603\0 (original application) MACI™ (matrix applied characterized autologous cultured chondrocytes) Autologous Implantation

Dear Patrick,

In Ron's absence could you consider the request below for an extension to submit the PVP by January 28, 2016. Please advise if this new date will be acceptable.

Many thanks in advance.

Regards,  
Margarita

Margarita Aguilera, M.Sc.  
Senior Regulatory Consultant – Vericel Corporation  
64 Sidney Street [Cambridge](#),  
MA 02139  
[maguilera@vcel.com](mailto:maguilera@vcel.com)  
Telephone: (617) 588-5661  
Mobile: (224) 659-2129  
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Margarita Aguilera  
**Sent:** Monday, January 18, 2016 3:45 PM  
**To:** 'Chamrin, Ronald'  
**Subject:** RE: Information Request for BLA 125603\0 (original application) MACI™ (matrix applied characterized autologous cultured chondrocytes) Autologous Implantation

Dear Ron,

Vericel requires additional time to submit the Pharmacovigilance Plan (PVP). We respectfully request an extension to submit the PVP by January 28, 2016. Please advise if this new date will be acceptable.

Best Regards,  
Margarita

Margarita Aguilera, M.Sc.  
Senior Regulatory Consultant – Vericel Corporation  
64 Sidney Street Cambridge,  
MA 02139  
[maguilera@vcel.com](mailto:maguilera@vcel.com)  
Telephone: (617) 588-5661  
Mobile: (224) 659-2129  
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Margarita Aguilera  
**Sent:** Wednesday, January 13, 2016 9:56 AM  
**To:** 'Chamrin, Ronald'  
**Subject:** RE: Information Request for BLA 125603\0 (original application) MACI™ (matrix applied characterized autologous cultured chondrocytes) Autologous Implantation

Dear Ron,

The following is to acknowledge receipt of the information request outlined below and to inform you that Vericel will plan to submit a Pharmacovigilance Plan (PVP) by January 22, 2016.

Best Regards,  
Margarita

Margarita Aguilera, M.Sc.  
Senior Regulatory Consultant – Vericel Corporation  
64 Sidney Street Cambridge,  
MA 02139  
[maguilera@vcel.com](mailto:maguilera@vcel.com)  
Telephone: (617) 588-5661  
Mobile: (224) 659-2129  
Facsimile: (734) 239-7401

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

---

**From:** Chamrin, Ronald [<mailto:Ronald.Chamrin@fda.hhs.gov>]

**Sent:** Tuesday, January 12, 2016 11:28 AM

**To:** Margarita Aguilera

**Subject:** Information Request for BLA 125603\0 (original application) MACI™ (matrix applied characterized autologous cultured chondrocytes) Autologous Implantation

**Importance:** High

Dear Ms. Aguilera:

**Information Request for BLA 125603\0 (original application) MACI™ (matrix applied characterized autologous cultured chondrocytes) Autologous Implantation:**

We note a document submitted in module 1.16 which discusses your assessment for Risk Evaluation and Mitigation Strategy (REMS). **Please also submit a Pharmacovigilance Plan (PVP) in module 1.16** as per the conventions described in the E2E Pharmacovigilance planning Guidance for Industry

(  
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073107.pdf>  
).

You may also refer to FDA Guidance for Industry on Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment  
(<http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126834.pdf>).

Please submit a PVP by **January 22, 2016** or identify a date by which you plan to submit the PVP.

Best,

Ron

**Ron Chamrin**

Regulatory Project Manager

Consumer Safety Officer

Food and Drug Administration

Center for Biologics Evaluation and Research

Office of Cellular, Tissue, and Gene Therapies

10903 New Hampshire Avenue

Silver Spring, MD 20993-0002

Phone 240-402-8269

Fax 301-595-1303

[ronald.chamrin@fda.hhs.gov](mailto:ronald.chamrin@fda.hhs.gov)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.